Results: 38 patients receiving dabigatran or rivaroxaban (6 and 32 respectively) were included in the BIG-ROX-P trial and platelet function was assessed. 35 patients (92%) suffered from AF, 3 patients (8%) were anticoagulated due to pulmonary embolism. Dabigatran doses were 110 mg or 150 mg twice daily, while rivaroxaban doses were from 2.5 mg twice daily to 20 mg per day. 18 patients (47%) received concomitant platelet inhibitors. TRAP, ADP or AA induced platelet aggregation was not different before and after application of dabigatran or rivaroxaban, respectively. In patients receiving concomitant platelet inhibitors no difference of TRAP, ADP or AA induced platelet aggregation was observed before and after application of dabigatran or rivaroxaban, respectively. Conclusion: Dabigatran or rivaroxaban had no influence on TRAP, ADP and AA induced platelet aggregation. Furthermore, they did not modulate the effect of concomitant platelet inhibitors.
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Real life efficacy and safety of rivaroxaban for stroke prevention in atrial fibrillation: updated results of the prospective NOAC registry (NCT01588119) J. Beyer-Westendorf, F. Ebertz, V. Gelbricht, K. Foerster, L. Tittl, S. Werth, C. Koehler. University Hospital "Carl Gustav Carus" Dresden, Center for Vascular Medicine, Dresden, Germany Background: In the ROCKET-AF trial, the novel oral anticoagulant (NOAC) rivaroxaban has been found to be at least as effective and safe as warfarin for stroke prevention in atrial fibrillation (SPAF). As a consequence, rivaroxaban has become approved in many countries. However, patients in RCT's present a selected population which is treated under a strict protocol and followed for a short period of time. Consequently, efficacy and safety of rivaroxaban need to be confirmed in unselected patients in daily care. Objectives: To evaluate the efficacy, safety and management issues of rivaroxaban anticoagulation in SPAF patients in daily care. Patients and methods: In the prospective, non-interventional Dresden NOAC registry a network of more than 230 physicians enrol eligible patients. Up to 2000 patients receive prospective follow up by phone visits by the registry office. All events are centrally adjudicated using standard definitions. Results: Until December 31th 2012, 1665 patients were registered. Of these, 967 patients received rivaroxaban for SPAF (51.6% male, mean age 74.4 years, mean CHADS-Score 2.4; 62.3% newly anticoagulated). Treatment adherence was high with 90.7% of patients still taking rivaroxaban at 9 month. During follow-up, 26 major cardiovascular events were observed (6.2 per 100 patient years; 11 ACS, 6 stroke, 4 TIA, 3 DVT, 1 type B dissection, 1 limb ischemia, see table 1). Furthermore, 277 bleeding events occurred, of which only 9 events were major bleedings (2.2 per 100 patient years). One fatal bleeding was observed (ICB). 13 patients died (3.1 per 100 patient years; 3 sudden cardiac death, 1 fatal bleeding, 1 aortic perforation, 8 of underlying diseases). Conclusion: In unselected patients in daily care, rivaroxaban is effective and Background: In the RELY trial, the novel oral anticoagulant (NOAC) dabigatran has been found to be at least as effective and safe as warfarin for stroke prevention in atrial fibrillation (SPAF). As a consequence, dabigatran has become approved in many countries. However, patients in RCT's present a selected population which is treated under a strict protocol and followed for a short period of time. 
Conclusion:
In unselected patients in daily care, dabigatran is effective and safe with low rates of cardiovascular or major bleeding events. However, about 25% of patients are switched to other anticoagulants within 9 months. Data on bleeding pattern and management will be presented.
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